Deca-Durabolin 100 mg Organon | SOU-0337

Application Deca-Durabolin 100 mg Organon in English sports and medicine.

Anabolic agent. When compared to testosterone, the latter has stronger, longer lasting anabolic and lower androgenic properties. It activates the regulatory genes in the cell nucleus by reacting with specific receptor proteins in the cell walls of the target organs and by synthesising the receptor protein-nandrolone complex, which transports the latter inside the cell to the hyaloplasm, where it travels to the nucleus. You can always buy this drug in Britain by placing an order on the website of our shop.

The androgenic effect is to stimulate the biosynthesis of nucleic acids and structural proteins, improve oxidative phosphorylation and tissue respiration in the striated muscles with the accumulation of ATP and creatine phosphate. Improves the fixation of Ca ions in the bones, increasing bone weight in osteoporosis, and increasing appetite and muscle mass.

Mechanism of action Deca-Durabolin 100 mg 

Accelerates Deca-Durabolin 100 mg in men and the development of secondary male sexual characteristics. Stimulates androgen-dependent glands (sexual, sebaceous), in high doses causes suppression of Leydig cells and reduces the biosynthesis of endogenous sex hormones due to inhibition of the pituitary follicle-stimulating and luteinizing hormones.

Deca-Durabolin 100 mg action is realized through the activation of repair processes in epithelium, bones and muscles by enhancing protein and cell organelle biosynthesis. Increases the absorption of amino acids from the intestine. Stimulates erythropoietin production and anabolic phenomena in bone marrow, which has an anti-anemic effect when iron preparations are administered together. Inhibits the synthesis of some plasma clotting factors in the liver, corrects the blood lipid profile, enhances the reabsorption of sodium and water in the kidneys, causing peripheral edema. It is effective in women with disseminated breast carcinoma.

Indications Deca-Durabolin 100 Organon

• Growing muscular dystrophy.
• Diabetic retinopathy.
• Progressive infantile atrophy.
• Activation of catabolic processes resulting in exhaustion (major operations, chronic infections, glucocorticosteroid-induced myopathy, burns, decubitus ulcers, severe trauma).
• Conditions characterised by a negative Ca2+ balance (prolonged glucocorticosteroid therapy, osteoporosis).
• Component of cytostatic treatment in oncological diseases (not including prostate cancer), inoperable breast carcinoma in post-menopausal period in women or after ovariectomy.